Abstract
Alzheimer’s disease (AD) is a type of neurodegenerative disorder which is responsible for many cognitive dysfunctions. According to the most accepted cholinergic hypothesis, cholinesterases have a major role in AD symptoms. The use of small molecules as inhibitors is one of the most useful strategies to control AD. In the present work, a series of N-phenylthiazol-2-amine derivatives was screened against acetylcholinesterase (AChE) from Electrophorus electricus and butyrylcholinesterase (BChE) from horse serum by using Ellman’s method, using neostigmine and donepezil as reference drugs. Some of the assayed compounds proved to be potent inhibitors for AChE and BChE activity. N-(2,3-dimethylphenyl)thiazol-2-amine, 3j was found to be the most active inhibitor among the series with IC50 value of 0.009 ± 0.002 µM and 0.646 ± 0.012 µM against AChE and BChE, respectively. Molecular docking studies were carried out in order to better understand the ligand binding site interactions.
Keywords: N-Phenylthiazol-2-amine, Alzheimer's disease, acetylcholinesterase, butyrylcholinesterase.
Graphical Abstract
Medicinal Chemistry
Title:Cholinesterase Inhibitory Activities of N-Phenylthiazol-2-Amine Derivatives and their Molecular Docking Studies
Volume: 11 Issue: 5
Author(s): Jamshed Iqbal, Mariya al-Rashida, Ayesha Babar, Abdul Hameed, Muhammad Siraj Khan, Munawar Ali Munawar and Ather Farooq Khan
Affiliation:
Keywords: N-Phenylthiazol-2-amine, Alzheimer's disease, acetylcholinesterase, butyrylcholinesterase.
Abstract: Alzheimer’s disease (AD) is a type of neurodegenerative disorder which is responsible for many cognitive dysfunctions. According to the most accepted cholinergic hypothesis, cholinesterases have a major role in AD symptoms. The use of small molecules as inhibitors is one of the most useful strategies to control AD. In the present work, a series of N-phenylthiazol-2-amine derivatives was screened against acetylcholinesterase (AChE) from Electrophorus electricus and butyrylcholinesterase (BChE) from horse serum by using Ellman’s method, using neostigmine and donepezil as reference drugs. Some of the assayed compounds proved to be potent inhibitors for AChE and BChE activity. N-(2,3-dimethylphenyl)thiazol-2-amine, 3j was found to be the most active inhibitor among the series with IC50 value of 0.009 ± 0.002 µM and 0.646 ± 0.012 µM against AChE and BChE, respectively. Molecular docking studies were carried out in order to better understand the ligand binding site interactions.
Export Options
About this article
Cite this article as:
Iqbal Jamshed, al-Rashida Mariya, Babar Ayesha, Hameed Abdul, Khan Siraj Muhammad, Munawar Ali Munawar and Khan Farooq Ather, Cholinesterase Inhibitory Activities of N-Phenylthiazol-2-Amine Derivatives and their Molecular Docking Studies, Medicinal Chemistry 2015; 11 (5) . https://dx.doi.org/10.2174/1573406411666141230104536
DOI https://dx.doi.org/10.2174/1573406411666141230104536 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design Easy Screening for Mild Alzheimer's Disease and Mild Cognitive Impairment from Elderly Speech
Current Alzheimer Research Lobar Atrophy in Frontotemporal Dementia: Diagnostic and Prognostic Implications
Current Alzheimer Research Lewy Bodies: A Spectator or Salient Killer?
CNS & Neurological Disorders - Drug Targets Abnormal Clock Gene Expression and Locomotor Activity Rhythms in Two Month-Old Female APPSwe/PS1dE9 Mice
Current Alzheimer Research Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Methylated MicroRNA Genes of the Developing Murine Palate
MicroRNA Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
Current Neuropharmacology Improving Metabolic Control Through Functional Foods
Current Medicinal Chemistry Antagonism of Endothelin (ETA and ETB) Receptors During Renovascular Hypertension-Induced Vascular Dementia Improves Cognition
Current Neurovascular Research Anti-Alzheimer, Antioxidant Activities and Flavonol Glycosides of Eryngium campestre L.
Current Chemical Biology Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Bleeding Complications in the Course of Treatment with Antidepressants in Elderly Patients
Current Psychiatry Reviews Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry